Pancreatic ductal adenocarcinoma (PDAC) has a poor response to the first-line chemotherapy drug gemcitabine. We previously identified stanniocalcin-1 as a gemcitabine-resistant-related gene, but its specific role and function in pancreatic cancer remain unclear. RT-qPCR and Western blot were used to evaluate differential protein and mRNA expressions. The biological functions of genes were determined using proliferation and drug-resistance experiments. Subcutaneous tumorigenesis experiment was performed on nude mice. Prognostic analysis was performed using public databases and our clinical data. We found HIF-1α-regulated STC1 expression mediated chemoresistance in pancreatic cancer. Deeper, we explored the action mechanism of STC1 and identified PI3K/AKT as the downstream signaling pathway of STC1. Furthermore, we analyzed clinical data and found that STC1 expression was related to the prognosis of gemcitabine-treated patients after surgery. In general, we proved the HIF-1α/STC1/PI3K-AKT axis participated in PDAC progression and chemoresistance, and STC1 may serve as a potential prognostic factor and therapeutic target for PDAC treatment.

中文翻译：

---

HIF-1α调节的斯钙素-1通过PI3K/AKT信号通路介导胰腺导管腺癌中吉西他滨耐药


胰腺导管腺癌（PDAC）对一线化疗药物吉西他滨的反应较差。我们之前将stanniocalcin-1鉴定为吉西他滨耐药相关基因，但其在胰腺癌中的具体作用和功能仍不清楚。 RT-qPCR和Western blot用于评估差异蛋白和mRNA表达。使用增殖和耐药性实验确定基因的生物学功能。裸鼠皮下致瘤实验。使用公共数据库和我们的临床数据进行预后分析。我们发现 HIF-1α 调节的 STC1 表达介导胰腺癌化疗耐药。更深入地探讨了STC1的作用机制，并确定PI3K/AKT为STC1的下游信号通路。此外，我们分析了临床数据，发现STC1表达与吉西他滨治疗患者术后的预后相关。总的来说，我们证明HIF-1α/STC1/PI3K-AKT轴参与了PDAC的进展和化疗耐药，并且STC1可能作为PDAC治疗的潜在预后因素和治疗靶点。